Antidepressant actions of ketamine: From molecular mechanisms to clinical practice

Current Opinion in Neurobiology

Volumn 30, Issue , 2015, Pages 139-143

  Monteggia, Lisa M ^a   Zarate, Carlos ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ELONGATION FACTOR 2 KINASE; KETAMINE; LANICEMINE; MEMANTINE; MK 065; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RILUZOLE; RO 256981; TRAXOPRODIL; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PILOT STUDY; PREFRONTAL CORTEX; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DEPRESSION; GENETICS; METABOLISM;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84920279509     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2014.12.004     Document Type: Review

References (43)

1. Berman R.M., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
2. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526. 10.1016/j.biopsych.2009.04.029.
3. Zarate C.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864. 10.1001/archpsyc.63.8.856.
4. Diazgranados N., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:93-802. 10.1001/archgenpsychiatry.2010.90.
5. Zarate C.A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71:39-946. 10.1016/j.biopsych.2011.12.010.
6. DiazGranados N., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010, 71:605-1611. 10.4088/JCP.09m05327blu.
7. Larkin G.L., Beautrais A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2012, 14:127-1131. 10.1017/S1461145711000629.
8. Zarate C.A., et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 2012, 72:31-338. 10.1016/j.biopsych.2012.03.004.
9. Zhao X., et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 2012, 74:4-314. 10.1111/j.1365-2125.2012.04198.x.
10. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15. 10.1038/npp.2011.181.
11. Pozzi L., Dorocic I.P., Wang X., Carlen M., Meletis K. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLOS ONE 2014, 9. e83879. 10.1371/journal.pone.0083879.
12. Miller O.H., et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife 2014, 3. 10.7554/eLife.03581.
13. Autry A.E., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:1-95. 10.1038/nature10130.
14. Nosyreva E., et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 2013, 33:990-7002. 10.1523/JNEUROSCI.4998-12.2013.
15. Ferguson J.M., Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007, 30:36-144. 10.1097/WNF.0b013e3180314ae7.
16. Lenze E.J., et al. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry 2012, 27:74-980. 10.1002/gps.2813.
17. Gideons E.S., Kavalali E.T., Monteggia L.M. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A 2014, 111:649-8654. 10.1073/pnas.1323920111.
18. Liu R.J., et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012, 71:96-1005. 10.1016/j.biopsych.2011.09.030.
19. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008, 63:42-649. 10.1016/j.biopsych.2007.09.019.
20. Monteggia L.M., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 2004, 101:827-10832. 10.1073/pnas.0402141101.
21. Monteggia L.M., et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007, 61:87-197. 10.1016/j.biopsych.2006.03.021.
22. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:38-258. 10.1124/pr.111.005108.
23. Li N., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:59-964. 10.1126/science.1190287.
24. Niciu M.J., Kelmendi B., Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 2012, 100:56-664. 10.1016/j.pbb.2011.08.008.
25. Niciu M.J., Henter I.D., Luckenbaugh D.A., Zarate C.A., Charney D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacool Toxicol 2014, 54:19-139. 10.1146/annurev-pharmtox-011613-135950.
26. Ibrahim L., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37:526-1533. 10.1038/npp.2011.338.
27. Mathews D.C., Henter I.D., Zarate C.A. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012, 72:313-1333. 10.2165/11633130-000000000-00000.
28. Beurel E., Song L., Jope R.S. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011, 16:68-1070. 10.1038/mp.2011.47.
29. Liu R.J., et al. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38:268-2277. 10.1038/npp.2013.128.
30. Murrough J.W., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013, 74:50-256. 10.1016/j.biopsych.2012.06.022.
31. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progr Neuro-psychopharmacol Biol Psychiatry 2009, 33:0-75. 10.1016/j.pnpbp.2008.10.005.
32. Maeng S., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:49-352. 10.1016/j.biopsych.2007.05.028.
33. Preskorn S.H., et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:31-637. 10.1097/JCP.0b013e31818a6cea.
34. Ibrahim L., et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012, 32:51-557. 10.1097/JCP.0b013e31825d70d6.
35. Zarate C.A., et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry 2013, 74:57-264. 10.1016/j.biopsych.2012.10.019.
36. Sanacora G., et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 2013, 10.1038/mp.2013.130.
37. Fu C.H., Steiner H., Costafreda S.G. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 2013, 52:5-83. 10.1016/j.nbd.2012.05.008.
38. Leuchter A.F., et al. Biomarkers to predict antidepressant response. Curr Psychiatry Rep 2010, 12:53-562. 10.1007/s11920-010-0160-4.
39. Zarate C.A., Mathews D.C., Furey M.L. Human biomarkers of rapid antidepressant effects. Biol Psychiatry 2013, 73:142-1155. 10.1016/j.biopsych.2012.11.031.
40. Niciu M.J., et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 2014, 75:e417-e423. 10.4088/JCP.13m08698.
41. Haile C.N., et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014, 17:31-336. 10.1017/S1461145713001119.
42. Kavalali E.T., Monteggia L.M. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012, 169:1150-1156.
43. Rush A.J. Ketamine for treatment-resistant depression: ready or not for clinical use?. Am J Psychiatry 2013, 170:79-1081. 10.1176/appi.ajp.2013.13081034.